Thermo Fisher Scientific/$TMO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Thermo Fisher Scientific
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Ticker
$TMO
Sector
Primary listing
NYSE
Employees
125,000
Headquarters
Website
TMO Metrics
BasicAdvanced
$215B
33.06
$17.32
0.91
$1.68
0.30%
Price and volume
Market cap
$215B
Beta
0.91
52-week high
$610.97
52-week low
$385.46
Average daily volume
2.3M
Dividend rate
$1.68
Financial strength
Current ratio
1.498
Quick ratio
0.946
Long term debt to equity
62.278
Total debt to equity
69.75
Dividend payout ratio (TTM)
9.48%
Interest coverage (TTM)
5.87%
Profitability
EBITDA (TTM)
10,835
Gross margin (TTM)
41.23%
Net profit margin (TTM)
15.02%
Operating margin (TTM)
18.72%
Effective tax rate (TTM)
7.64%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
4.94%
Return on equity (TTM)
13.12%
Valuation
Price to earnings (TTM)
33.057
Price to revenue (TTM)
4.96
Price to book
4.24
Price to tangible book (TTM)
-14.92
Price to free cash flow (TTM)
35.5
Free cash flow yield (TTM)
2.82%
Free cash flow per share (TTM)
16.124
Dividend yield (TTM)
0.29%
Forward dividend yield
0.30%
Growth
Revenue change (TTM)
3.22%
Earnings per share change (TTM)
8.54%
3-year revenue growth (CAGR)
-0.33%
10-year revenue growth (CAGR)
10.04%
3-year earnings per share growth (CAGR)
-0.89%
10-year earnings per share growth (CAGR)
13.43%
3-year dividend per share growth (CAGR)
13.14%
10-year dividend per share growth (CAGR)
10.84%
What the Analysts think about TMO
Analyst ratings (Buy, Hold, Sell) for Thermo Fisher Scientific stock.
Bulls say / Bears say
Thermo Fisher’s third-quarter revenue of $11.12 billion topped the $10.91 billion consensus, while adjusted EPS beat forecasts at $5.79 versus $5.49, driven by strong demand for laboratory tools and biopharma technologies (Reuters )
The company is nearing a $9.4 billion acquisition of Clario to bolster its clinical trial data management and digital health offerings, marking its third major deal this year and expanding its high-growth services portfolio (Reuters )
Thermo Fisher has initiated the sale of its microbiology and related diagnostics units for about $4 billion, a strategic move to divest lower-growth assets and reallocate capital to its faster-growing bioprocessing and life sciences segments (Reuters )
Specialty diagnostics assets generating approximately $1.4 billion in annual sales and $300 million in adjusted earnings are being shopped for around $4 billion, highlighting underperformance and the risk of revenue loss in this division (Reuters )
Thermo Fisher’s growth strategy relies heavily on acquisitions, with three major deals in 2025—including the $4.1 billion Solventum purification business and the pending $9.4 billion Clario acquisition—raising integration challenges and potential dilutive effects (Reuters )
The completion of a $2.48 billion senior notes offering across four tranches to fund corporate purposes and acquisitions increases financial leverage and interest obligations, potentially pressuring the company’s credit metrics (Reuters )
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
TMO Financial Performance
Revenues and expenses
TMO Earnings Performance
Company profitability
TMO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Thermo Fisher Scientific stock?
Thermo Fisher Scientific (TMO) has a market cap of $215B as of November 09, 2025.
What is the P/E ratio for Thermo Fisher Scientific stock?
The price to earnings (P/E) ratio for Thermo Fisher Scientific (TMO) stock is 33.06 as of November 09, 2025.
Does Thermo Fisher Scientific stock pay dividends?
Yes, the Thermo Fisher Scientific (TMO) stock pays dividends to shareholders. As of November 09, 2025, the dividend rate is $1.68 and the yield is 0.3%. Thermo Fisher Scientific has a payout ratio of 9.48% on a trailing twelve-month basis.
When is the next Thermo Fisher Scientific dividend payment date?
The next Thermo Fisher Scientific (TMO) dividend payment is scheduled for January 15, 2026.
What is the beta indicator for Thermo Fisher Scientific?
Thermo Fisher Scientific (TMO) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.